NASDAQ:IKT Inhibikase Therapeutics Q4 2025 Earnings Results & Report $1.97 +0.06 (+3.14%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.96 0.00 (-0.25%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Inhibikase Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 26, 2026. The company reported EPS of -$0.09 versus the -$0.12 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 26, 2026TimeAfter Market Closes Inhibikase Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.12Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersInhibikase Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Inhibikase Therapeutics Q4 2025 Earnings FAQ Did Inhibikase Therapeutics beat earnings estimates for Q4 2025? Inhibikase Therapeutics (NASDAQ:IKT) reported earnings of -$0.09 per share for Q4 2025, beating the consensus estimate of -$0.12. The report was announced on Thursday, March 26, 2026. Inhibikase Therapeutics Earnings HeadlinesHead-To-Head Analysis: Inhibikase Therapeutics (NASDAQ:IKT) versus Talphera (NASDAQ:TLPH)October 7, 2026 | americanbankingnews.comInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 11 at 1:00 AM | Altimetry (Ad)Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Nuvation Bio (NUVB)September 18, 2026 | theglobeandmail.comInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityAugust 11, 2026 | globenewswire.comInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHJuly 23, 2026 | globenewswire.comSee More Inhibikase Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email. Email Address About Inhibikase TherapeuticsInhibikase Therapeutics (NASDAQ:IKT) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for diseases associated with abnormal protein accumulation. The company’s research has centered on neurological disorders, including Parkinson’s disease and related synucleinopathies, as well as selected infectious and cancer-related indications. Its lead investigational product, IkT-148009, is an orally administered, brain-penetrant inhibitor of Abelson tyrosine kinase, or c-Abl. Inhibikase is evaluating the candidate for its potential to address disease mechanisms linked to alpha-synuclein pathology and neurodegeneration, with clinical development focused primarily on Parkinson’s disease and related disorders. Inhibikase Therapeutics is headquartered in Atlanta, Georgia, and its programs are being developed through clinical research conducted in the United States and other applicable trial locations. The company was founded by Milton Werner, who has served as its president and chief executive officer. Its common stock trades on the Nasdaq Capital Market under the symbol IKT.View Inhibikase Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
